Axsome Therapeutics (AXSM) said Tuesday that a late-stage trial of AXS-12, a narcolepsy drug candidate, had achieved its primary endpoint of statistically significant reduction in cataplexy attacks.
Treated patients who were switched to placebo had worsened attacks with an increase of 10.29 attacks per week, whereas those who continued AXS-12 treatment saw an increase of 1.32, Axsome said.
The drug also showed statistical significance in improving cognition and overall narcolepsy symptoms, the company said.
Shares of the company were up 2.8% in recent Tuesday premarket activity.
Price: 102.00, Change: +4.50, Percent Change: +4.6
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.